Differential Risk of Death in Older Residents in Nursing Homes Prescribed Specific Antipsychotic Drugs: Population Based Cohort Study

DSpace/Manakin Repository

Differential Risk of Death in Older Residents in Nursing Homes Prescribed Specific Antipsychotic Drugs: Population Based Cohort Study

Citable link to this page

. . . . . .

Title: Differential Risk of Death in Older Residents in Nursing Homes Prescribed Specific Antipsychotic Drugs: Population Based Cohort Study
Author: Gerhard, T; Crystal, S; Olfson, M; Huybrechts, Krista F.g.; Avorn, Jerry Lewis; Levin, Robert Marc; Lucas, J. A.; Schneeweiss, Sebastian

Note: Order does not necessarily reflect citation order of authors.

Citation: Huybrechts, K. F., T. Gerhard, S. Crystal, M. Olfson, J. Avorn, R. Levin, J. A. Lucas, and S. Schneeweiss. 2012. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: Population based cohort study. BMJ 344: e977.
Full Text & Related Files:
Abstract: Objective: To assess risks of mortality associated with use of individual antipsychotic drugs in elderly residents in nursing homes. Design Population based cohort study with linked data from Medicaid, Medicare, the Minimum Data Set, the National Death Index, and a national assessment of nursing home quality. Setting: Nursing homes in the United States. Participants: 75 445 new users of antipsychotic drugs (haloperidol, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone). All participants were aged ≥65, were eligible for Medicaid, and lived in a nursing home in 2001-5. Main outcome measures: Cox proportional hazards models were used to compare 180 day risks of all cause and cause specific mortality by individual drug, with propensity score adjustment to control for potential confounders. Results: Compared with risperidone, users of haloperidol had an increased risk of mortality (hazard ratio 2.07, 95% confidence interval 1.89 to 2.26) and users of quetiapine a decreased risk (0.81, 0.75 to 0.88). The effects were strongest shortly after the start of treatment, remained after adjustment for dose, and were seen for all causes of death examined. No clinically meaningful differences were observed for the other drugs. There was no evidence that the effect measure modification in those with dementia or behavioural disturbances. There was a dose-response relation for all drugs except quetiapine. Conclusions: Though these findings cannot prove causality, and we cannot rule out the possibility of residual confounding, they provide more evidence of the risk of using these drugs in older patients, reinforcing the concept that they should not be used in the absence of clear need. The data suggest that the risk of mortality with these drugs is generally increased with higher doses and seems to be highest for haloperidol and least for quetiapine.
Published Version: doi:10.1136/bmj.e977
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285717/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:9313074

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters